HomeNDC LookupRxCUI directory › RxCUI 1364515

Bedaquiline 100 MG Oral Tablet [Sirturo] — RxCUI 1364515

RxNorm drug concept · Semantic branded drug
RxCUI 1364515 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1364515
Official nameBedaquiline 100 MG Oral Tablet [Sirturo]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asSirturo 100 MG Oral Tablet; Sirturo 100 MG (as bedaquiline fumarate 120.9 MG) Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)145 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bedaquiline: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Sirturo always needs to be used alongside at least three other drugs that your TB bacteria are sensitive to. If you take it alone, the bacteria are much more likely to develop resi...
  • Why do I have to take Sirturo with other TB medicines? Can't it work on its own?
  • Sirturo affects the electrical activity in your heart in a way that can — in some people — lead to a dangerous irregular heartbeat. This is called QTc prolongation. It doesn't mean...
  • Why do I need heart monitoring while I'm on this medication?
📖 Read our full Bedaquiline guide →

🕸️ Concept Web — How Bedaquiline 100 MG Oral Tablet [Sirturo] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Bedaquiline 100 MG Oral Tablet [Sirturo] RxCUI 1364515

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Bedaquiline 1364504
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Sirturo 1364510
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Bedaquiline Oral Tablet 1364508
    • Bedaquiline Oral Product 1364506
    • Bedaquiline Pill 1364507
    • Bedaquiline Oral Tablet [Sirturo] 1364512
    • Sirturo Oral Product 1364513
    • Sirturo Pill 1364514
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Bedaquiline 100 MG Oral Tablet SCD · 1364509
  • Bedaquiline 100 MG SCDC · 1364505
  • Bedaquiline Oral Tablet SCDF · 1364508
  • Bedaquiline Oral Product SCDG · 1364506
  • Bedaquiline Pill SCDG · 1364507

Brand-Name Concepts

  • Bedaquiline 100 MG [Sirturo] SBDC · 1364511
  • Bedaquiline Oral Tablet [Sirturo] SBDF · 1364512
  • Sirturo Oral Product SBDG · 1364513
  • Sirturo Pill SBDG · 1364514
  • Sirturo BN · 1364510

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 1364515 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
59676-0701-01 188 TABLET in 1 BOTTLE (59676-701-01) SIRTURO Janssen Products, LP 2012-12-28
59676-0702-60 60 TABLET in 1 BOTTLE (59676-702-60) SIRTURO Janssen Products, LP 2020-05-27
Observed labelers: Janssen Products, LP (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.